Back

Artificial intelligence-driven precision medicine identifies prognostic WNT pathway alterations in AA colorectal cancer patients treated with FOLFOX

Minas, T. Z.; Waldrup, B.; Carranza, F. G.; Manjarrez, S.; Velazquez-Villarreal, E.

2026-05-21 gastroenterology
10.64898/2026.05.14.26353255 medRxiv
Show abstract

Background: African Americans (AA) experience disproportionate burden of colorectal cancer (CRC). Dysregulation of the Wingless-related integration site (WNT) pathways contributes to tumor progression, yet their prognostic roles in FOLFOX-treated CRC among AA patients remain understudied. Methods: We analyzed 2,562 CRC cases stratified by ancestry, age at onset, and FOLFOX treatment using Fisher's exact, chi-square, and Kaplan-Meier analyses from AACR Project GENIE and cBioPortal databases. To enhance data integration and interpretation, we applied AI-HOPE and AI-HOPE-WNT, conversational artificial intelligence (AI) platforms designed to integrate clinical, genomic, and treatment data through natural language-driven queries. Results: Overall survival analyses showed that early-onset CRC (EOCRC) AA patients treated with FOLFOX who had WNT pathway alterations experienced significantly better survival (p = 0.035). WNT pathway alterations were less frequent in late-onset AA patients treated with FOLFOX compared to those not treated (80% vs. 92%; p = 0.05). Conclusions: Chemotherapy exposure may influence pathway-specific mutation frequencies across ancestry and disease stage. AI-enabled integrative analyses highlight the potential of conversational AI platforms to accelerate biomarker discovery and reveal ancestry- and treatment-specific vulnerabilities in CRC.

Matching journals

The top 9 journals account for 50% of the predicted probability mass.

1
Cancers
213 papers in training set
Top 0.3%
11.9%
2
International Journal of Cancer
49 papers in training set
Top 0.1%
9.8%
3
BMC Cancer
67 papers in training set
Top 0.2%
6.7%
4
Scientific Reports
3612 papers in training set
Top 16%
5.5%
5
Communications Medicine
113 papers in training set
Top 0.5%
4.9%
6
Nature Communications
5641 papers in training set
Top 34%
3.4%
7
npj Genomic Medicine
36 papers in training set
Top 0.1%
3.2%
8
British Journal of Cancer
49 papers in training set
Top 0.4%
3.2%
9
PLOS ONE
5266 papers in training set
Top 38%
3.2%
50% of probability mass above
10
Clinical Cancer Research
64 papers in training set
Top 0.7%
2.6%
11
Molecular Oncology
55 papers in training set
Top 0.4%
2.6%
12
Frontiers in Oncology
103 papers in training set
Top 1%
2.4%
13
iScience
1154 papers in training set
Top 11%
2.4%
14
EMBO Molecular Medicine
95 papers in training set
Top 0.6%
2.1%
15
The Journal of Molecular Diagnostics
39 papers in training set
Top 0.3%
2.0%
16
Translational Oncology
21 papers in training set
Top 0.3%
1.9%
17
Biomedicines
67 papers in training set
Top 1%
1.7%
18
Nature Medicine
125 papers in training set
Top 1%
1.7%
19
Journal of Medical Internet Research
87 papers in training set
Top 2%
1.3%
20
npj Precision Oncology
53 papers in training set
Top 1%
1.3%
21
Cancer Medicine
26 papers in training set
Top 0.8%
1.1%
22
Cell Reports Medicine
153 papers in training set
Top 3%
1.1%
23
American Journal of Gastroenterology
17 papers in training set
Top 0.3%
1.1%
24
Frontiers in Medicine
120 papers in training set
Top 3%
1.0%
25
Heliyon
152 papers in training set
Top 6%
1.0%
26
Journal of Personalized Medicine
28 papers in training set
Top 0.9%
1.0%
27
European Journal of Cancer
11 papers in training set
Top 0.4%
0.8%
28
Cancer Immunology, Immunotherapy
12 papers in training set
Top 0.3%
0.8%
29
Gut
40 papers in training set
Top 0.9%
0.8%
30
Genome Medicine
183 papers in training set
Top 5%
0.8%